SHB17 Antibody

What is HSD17B11 and what are its primary biological functions?

HSD17B11 (17-beta-hydroxysteroid dehydrogenase 11) is an enzyme involved in steroid metabolism with specific activity in androgen pathways. By controlling hormone levels, HSD17B11 impacts cellular functions related to metabolism, growth, and reproduction, reinforcing its importance in maintaining proper physiological conditions . The protein can convert androstan-3-alpha,17-beta-diol (3-alpha-diol) to androsterone in vitro, suggesting participation in androgen metabolism during steroidogenesis . Its mechanism may involve metabolizing compounds that stimulate steroid synthesis and/or generating metabolites that inhibit steroidogenesis . Importantly, HSD17B11 has been identified as a tumor-associated antigen in cutaneous T-cell lymphoma, suggesting potential roles in cancer biology .

What detection methods are suitable for HSD17B11 antibody application?

Based on current validation, Western blot (WB) is the primary recommended application for HSD17B11 antibody . When using this technique, researchers should note the optimal dilution ratio of 1/500 for the antibody (ab167686), as demonstrated in experimental validations . The antibody has been successfully tested against transfected cell lysates containing human HSD17B11, confirming its specificity for the target protein . Researchers should establish proper controls when implementing the antibody in their Western blot protocols to ensure reliable results.

What is the specificity profile of commercially available HSD17B11 antibodies?

The polyclonal HSD17B11 antibody (ab167686) has demonstrated specificity toward human HSD17B11 in transfected cell lysate samples . The antibody was generated using a recombinant full-length protein corresponding to human HSD17B11 as the immunogen . Researchers should be aware that while the antibody has been tested specifically with human samples, cross-reactivity with other species may occur based on sequence homology, although this would require experimental validation . When designing experiments, it is crucial to consider the antibody's specificity profile to ensure accurate interpretation of results.

What are the alternative names and classifications for HSD17B11?

HSD17B11 is known by several alternative names in the scientific literature, including DHRS8, PAN1B, SDR16C2, PSEC0029, UNQ207/PRO233, Estradiol 17-beta-dehydrogenase 11, 17-beta-hydroxysteroid dehydrogenase XI, Cutaneous T-cell lymphoma-associated antigen HD-CL-03, Dehydrogenase/reductase SDR family member 8, Retinal short-chain dehydrogenase/reductase 2, and Short chain dehydrogenase/reductase family 16C member 2 . Understanding these alternative nomenclatures is essential when conducting literature reviews or designing experiments, as different research groups may use different terminology to refer to the same protein.

How does HSD17B11 contribute to steroid metabolism regulation?

HSD17B11 appears to play a selective role in steroid metabolism regulation, with notable substrate specificity. The enzyme shows activity in converting androstan-3-alpha,17-beta-diol to androsterone but has no documented activity toward dehydroepiandrosterone (DHEA) or 4-androste-3,17-dione (A-dione) . It demonstrates only slight activity in converting testosterone to A-dione . This selective substrate specificity suggests HSD17B11 occupies a specific niche in the steroid metabolism network, potentially regulating levels of specific androgens rather than broadly affecting all steroid hormones. Researchers investigating steroid metabolism pathways should consider these selective activities when designing experiments or interpreting results involving HSD17B11.

What is the relationship between HSD17B11 and cutaneous T-cell lymphoma?

HSD17B11 has been identified as a tumor-associated antigen in cutaneous T-cell lymphoma (CTCL), where it is also known as CTCL-associated antigen HD-CL-03 . This association suggests potential applications in cancer research, particularly in diagnostic or therapeutic approaches targeting CTCL. While the exact mechanism by which HSD17B11 contributes to CTCL pathophysiology is not fully detailed in the available literature, its identification as a tumor-associated antigen indicates altered expression or functionality in CTCL cells compared to normal T cells. Researchers studying CTCL may find HSD17B11 antibodies valuable for investigating expression patterns, potential biomarker applications, or as targets for experimental therapeutic approaches.

How can biophysics-informed modeling enhance antibody specificity studies for targets like HSD17B11?

Recent advances in antibody research demonstrate that biophysics-informed modeling combined with high-throughput sequencing can disentangle multiple binding modes associated with specific ligands . When applied to antibodies targeting proteins like HSD17B11, this approach could help identify antibodies with customized specificity profiles, either with specific high affinity for HSD17B11 or with controlled cross-specificity for related family members . The methodology involves identifying different binding modes associated with particular ligands and using this information to design antibodies with desired specificity characteristics . Researchers studying HSD17B11 could potentially apply these techniques to develop more specific antibodies or to better understand the binding characteristics of existing antibodies.

What approaches can be used to validate HSD17B11 antibody specificity across multiple experimental conditions?

Validating antibody specificity for targets like HSD17B11 requires a multi-faceted approach. Researchers should consider implementing:

• Positive controls using transfected cell lysates overexpressing HSD17B11, as demonstrated in existing protocols

• Negative controls using knockout or knockdown models

• Comparative analysis across multiple antibodies targeting different epitopes of HSD17B11

• Cross-validation with orthogonal techniques such as mass spectrometry

Drawing from broader antibody research principles, researchers could also apply methodologies from phage display experiments to validate antibody specificity . Such approaches have been successful in disentangling binding modes for chemically similar ligands and could be adapted to validate HSD17B11 antibody specificity across experimental conditions .

What are the optimal conditions for Western blot analysis using HSD17B11 antibody?

For Western blot analysis using the HSD17B11 antibody (ab167686), researchers should follow these methodological guidelines:

• Use a dilution ratio of 1/500 for the antibody preparation

• Include appropriate positive controls, such as HSD17B11 transfected cell lysates

• Load approximately 15 μL of transfected cell lysate when using it as a positive control

• Follow standard Western blot protocols, including proper sample preparation, SDS-PAGE separation, transfer to membrane, blocking, and detection

• Consider optimization of secondary antibody concentrations and detection systems based on laboratory-specific equipment and sensitivity requirements

These conditions have been validated experimentally and should provide a starting point for researchers implementing the antibody in their Western blot experiments .

How can high-throughput sequencing approaches be integrated with antibody selection for improved HSD17B11 detection?

Integration of high-throughput sequencing with antibody selection represents an advanced approach that could enhance HSD17B11 antibody development. This methodology, as demonstrated in recent antibody research, involves:

• Performing phage display experiments with antibody libraries against specific targets

• Collecting phages at each step of the selection protocol to monitor antibody library composition

• Using high-throughput sequencing to analyze selection outcomes

• Applying computational models that associate each potential ligand with a distinct binding mode

• Using these models to predict and generate specific antibody variants with customized specificity profiles

This approach has shown promise in designing antibodies with both specific and cross-specific binding properties . Applied to HSD17B11 research, these methodologies could potentially yield antibodies with enhanced specificity and sensitivity, particularly valuable for distinguishing between HSD17B11 and closely related family members.

What strategies can be employed to minimize non-specific binding when using HSD17B11 antibody?

To minimize non-specific binding when using HSD17B11 antibody, researchers should consider implementing several strategic approaches:

• Optimizing blocking conditions using appropriate blocking buffers (BSA, non-fat milk, or commercial alternatives)

• Carefully titrating primary antibody concentration, starting with the recommended 1/500 dilution and adjusting as necessary

• Implementing stringent washing protocols between antibody incubation steps

• Pre-absorbing the antibody with non-specific proteins if cross-reactivity is observed

• Including appropriate negative controls in experimental design to identify potential non-specific binding

These methodological considerations are particularly important when working with polyclonal antibodies like the available HSD17B11 antibody (ab167686) , which may contain a heterogeneous mixture of antibodies recognizing different epitopes on the target protein.

How can HSD17B11 antibody contribute to understanding steroid metabolism in hormone-dependent cancers?

Given HSD17B11's role in androgen metabolism and its association with cutaneous T-cell lymphoma , its antibody can be a valuable tool for investigating steroid metabolism in hormone-dependent cancers. Research applications include:

• Examining HSD17B11 expression levels across different cancer types, particularly those with known hormonal influences

• Investigating correlations between HSD17B11 expression and clinical outcomes in hormone-dependent cancers

• Studying potential changes in HSD17B11 activity during cancer progression or in response to hormone therapy

• Exploring the enzyme's potential role in resistance mechanisms to endocrine therapies

By applying HSD17B11 antibody in these research contexts, investigators may gain insights into the complex interplay between steroid metabolism and cancer biology, potentially identifying new therapeutic targets or biomarkers.

What are the considerations for using HSD17B11 antibody in immunohistochemistry studies?

While the available data primarily validates HSD17B11 antibody for Western blot applications , researchers interested in immunohistochemistry (IHC) studies should consider:

• Performing extensive validation studies before applying the antibody to IHC, including positive and negative controls

• Optimizing fixation and antigen retrieval methods, as these can significantly impact antibody performance in tissue sections

• Comparing results with alternative detection methods to confirm specificity

• Including appropriate controls for tissue-specific autofluorescence or endogenous peroxidase activity

• Considering the use of multiplexed immunohistochemistry to examine HSD17B11 in relation to other markers

These methodological considerations are crucial for generating reliable and interpretable immunohistochemistry data, particularly when using antibodies that have not been extensively validated for this specific application.